Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II --In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in DISSOLVE II --75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of therapy with no infusion reactions or new safety signals --Favorable safety profile with 3.4% of patients with infusion reactions at high dose WATERTOWN, Mass./STOCHOLM SWEDEN March 21, 2023 -- Selecta Biosciences, Inc. (NASDAQ: